MovDisordV3, PascalFrancis, Corpus, bibRecord, 001318

Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations

Identifieur interne : 001318 ( PascalFrancis/Corpus ); précédent : 001317; suivant : 001319

Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations

Auteurs : Hubert H. Fernandez ; Dag Aarsland ; Gilles Fenelon ; Joseph H. Friedman ; Laura Marsh ; Alexander I. Troster ; Werner Poewe ; Olivier Rascol ; Cristina Sampaio ; Glenn T. Stebbins ; Christopher G. Goetz

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0199275

Descripteurs français

Pascal (Inist)
- Psychose, Maladie de Parkinson, Hallucination, Délire, Pathologie du système nerveux, Recommandation.

English descriptors

KwdEn :
- Delusion, Hallucination, Nervous system diseases, Parkinson disease, Psychosis, Recommendation.

Abstract

Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as "recommended" or "suggested" based on the fulfilling-defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations`
A11	`01`	`1`		`@1 FERNANDEZ (Hubert H.)`
A11	`02`	`1`		`@1 AARSLAND (Dag)`
A11	`03`	`1`		`@1 FENELON (Gilles)`
A11	`04`	`1`		`@1 FRIEDMAN (Joseph H.)`
A11	`05`	`1`		`@1 MARSH (Laura)`
A11	`06`	`1`		`@1 TROSTER (Alexander I.)`
A11	`07`	`1`		`@1 POEWE (Werner)`
A11	`08`	`1`		`@1 RASCOL (Olivier)`
A11	`09`	`1`		`@1 SAMPAIO (Cristina)`
A11	`10`	`1`		`@1 STEBBINS (Glenn T.)`
A11	`11`	`1`		`@1 GOETZ (Christopher G.)`
A14	`01`			`@1 Department of Neurology, McKnight Brain Institute/University of Florida @2 Gainesville, Florida @3 USA @Z 1 aut.`
A14	`02`			`@1 Stavanger University Hospital, Centre for Clinical Neuroscience Research @2 Stavanger @3 NOR @Z 2 aut.`
A14	`03`			`@1 Department of Neurology, Hôpital Henri-Mondor @2 Crétil @3 FRA @Z 3 aut.`
A14	`04`			`@1 Department of Clinical Neuroscience, Brown University Medical School @2 Providence, Rhode Island @3 USA @Z 4 aut.`
A14	`05`			`@1 Department of Psychiatry, Johns Hopkins University @2 Baltimore, Maryland @3 USA @Z 5 aut.`
A14	`06`			`@1 Department of Neurology, University of North Carolina @2 Chapel Hill, North Carolina @3 USA @Z 6 aut.`
A14	`07`			`@1 Department of Neurology, Medical University of Innsbruck @2 Innsbruck @3 AUT @Z 7 aut.`
A14	`08`			`@1 Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine @2 Toulouse @3 FRA @Z 8 aut.`
A14	`09`			`@1 Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa @2 Lisboa @3 PRT @Z 9 aut.`
A14	`10`			`@1 Department of Neurological Sciences, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 10 aut. @Z 11 aut.`
A20				`@1 484-500`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000183361080020`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 85 ref.`
A47	`01`	`1`		`@0 08-0199275`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as "recommended" or "suggested" based on the fulfilling-defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Psychose @5 01`
C03	`01`	`X`	`ENG`	`@0 Psychosis @5 01`
C03	`01`	`X`	`SPA`	`@0 Psicosis @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Hallucination @5 03`
C03	`03`	`X`	`ENG`	`@0 Hallucination @5 03`
C03	`03`	`X`	`SPA`	`@0 Alucinación @5 03`
C03	`04`	`X`	`FRE`	`@0 Délire @5 04`
C03	`04`	`X`	`ENG`	`@0 Delusion @5 04`
C03	`04`	`X`	`SPA`	`@0 Delirio @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 05`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 05`
C03	`06`	`X`	`FRE`	`@0 Recommandation @5 09`
C03	`06`	`X`	`ENG`	`@0 Recommendation @5 09`
C03	`06`	`X`	`SPA`	`@0 Recomendación @5 09`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 126`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0199275 INIST
ET :	Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations
AU :	FERNANDEZ (Hubert H.); AARSLAND (Dag); FENELON (Gilles); FRIEDMAN (Joseph H.); MARSH (Laura); TROSTER (Alexander I.); POEWE (Werner); RASCOL (Olivier); SAMPAIO (Cristina); STEBBINS (Glenn T.); GOETZ (Christopher G.)
AF :	Department of Neurology, McKnight Brain Institute/University of Florida/Gainesville, Florida/Etats-Unis (1 aut.); Stavanger University Hospital, Centre for Clinical Neuroscience Research/Stavanger/Norvège (2 aut.); Department of Neurology, Hôpital Henri-Mondor/Crétil/France (3 aut.); Department of Clinical Neuroscience, Brown University Medical School/Providence, Rhode Island/Etats-Unis (4 aut.); Department of Psychiatry, Johns Hopkins University/Baltimore, Maryland/Etats-Unis (5 aut.); Department of Neurology, University of North Carolina/Chapel Hill, North Carolina/Etats-Unis (6 aut.); Department of Neurology, Medical University of Innsbruck/Innsbruck/Autriche (7 aut.); Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine/Toulouse/France (8 aut.); Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa/Lisboa/Portugal (9 aut.); Department of Neurological Sciences, Rush University Medical Center/Chicago, Illinois/Etats-Unis (10 aut., 11 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 4; Pp. 484-500; Bibl. 85 ref.
LA :	Anglais
EA :	Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as "recommended" or "suggested" based on the fulfilling-defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time.
CC :	002B17; 002B17G
FD :	Psychose; Maladie de Parkinson; Hallucination; Délire; Pathologie du système nerveux; Recommandation
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Psychosis; Parkinson disease; Hallucination; Delusion; Nervous system diseases; Recommendation
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Psicosis; Parkinson enfermedad; Alucinación; Delirio; Sistema nervioso patología; Recomendación
LO :	INIST-20953.354000183361080020
ID :	08-0199275

Links to Exploration step

Pascal:08-0199275

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, McKnight Brain Institute/University of Florida</s1>
<s2>Gainesville, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name>
<affiliation><inist:fA14 i1="02"><s1>Stavanger University Hospital, Centre for Clinical Neuroscience Research</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fenelon, Gilles" sort="Fenelon, Gilles" uniqKey="Fenelon G" first="Gilles" last="Fenelon">Gilles Fenelon</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Hôpital Henri-Mondor</s1>
<s2>Crétil</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Clinical Neuroscience, Brown University Medical School</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Psychiatry, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Troster">Alexander I. Troster</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Medical University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="08"><s1>Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="09"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0199275</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0199275 INIST</idno>
<idno type="RBID">Pascal:08-0199275</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001318</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, McKnight Brain Institute/University of Florida</s1>
<s2>Gainesville, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name>
<affiliation><inist:fA14 i1="02"><s1>Stavanger University Hospital, Centre for Clinical Neuroscience Research</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fenelon, Gilles" sort="Fenelon, Gilles" uniqKey="Fenelon G" first="Gilles" last="Fenelon">Gilles Fenelon</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Hôpital Henri-Mondor</s1>
<s2>Crétil</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Clinical Neuroscience, Brown University Medical School</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Psychiatry, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Troster">Alexander I. Troster</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Medical University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="08"><s1>Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="09"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Delusion</term>
<term>Hallucination</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Recommendation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Psychose</term>
<term>Maladie de Parkinson</term>
<term>Hallucination</term>
<term>Délire</term>
<term>Pathologie du   système nerveux</term>
<term>Recommandation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as "recommended" or "suggested" based on the fulfilling-defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FERNANDEZ (Hubert H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>AARSLAND (Dag)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FENELON (Gilles)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FRIEDMAN (Joseph H.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MARSH (Laura)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TROSTER (Alexander I.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SAMPAIO (Cristina)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>STEBBINS (Glenn T.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, McKnight Brain Institute/University of Florida</s1>
<s2>Gainesville, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Stavanger University Hospital, Centre for Clinical Neuroscience Research</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Hôpital Henri-Mondor</s1>
<s2>Crétil</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Clinical Neuroscience, Brown University Medical School</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Psychiatry, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Medical University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>484-500</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000183361080020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>85 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0199275</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as "recommended" or "suggested" based on the fulfilling-defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Psychose</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Hallucination</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Hallucination</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Alucinación</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Délire</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Delusion</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Delirio</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Recommandation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Recommendation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Recomendación</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>126</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0199275 INIST</NO>
<ET>Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations</ET>
<AU>FERNANDEZ (Hubert H.); AARSLAND (Dag); FENELON (Gilles); FRIEDMAN (Joseph H.); MARSH (Laura); TROSTER (Alexander I.); POEWE (Werner); RASCOL (Olivier); SAMPAIO (Cristina); STEBBINS (Glenn T.); GOETZ (Christopher G.)</AU>
<AF>Department of Neurology, McKnight Brain Institute/University of Florida/Gainesville, Florida/Etats-Unis (1 aut.); Stavanger University Hospital, Centre for Clinical Neuroscience Research/Stavanger/Norvège (2 aut.); Department of Neurology, Hôpital Henri-Mondor/Crétil/France (3 aut.); Department of Clinical Neuroscience, Brown University Medical School/Providence, Rhode Island/Etats-Unis (4 aut.); Department of Psychiatry, Johns Hopkins University/Baltimore, Maryland/Etats-Unis (5 aut.); Department of Neurology, University of North Carolina/Chapel Hill, North Carolina/Etats-Unis (6 aut.); Department of Neurology, Medical University of Innsbruck/Innsbruck/Autriche (7 aut.); Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine/Toulouse/France (8 aut.); Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa/Lisboa/Portugal (9 aut.); Department of Neurological Sciences, Rush University Medical Center/Chicago, Illinois/Etats-Unis (10 aut., 11 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 4; Pp. 484-500; Bibl. 85 ref.</SO>
<LA>Anglais</LA>
<EA>Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as "recommended" or "suggested" based on the fulfilling-defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time.</EA>
<CC>002B17; 002B17G</CC>
<FD>Psychose; Maladie de Parkinson; Hallucination; Délire; Pathologie du   système nerveux; Recommandation</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Psychosis; Parkinson disease; Hallucination; Delusion; Nervous system diseases; Recommendation</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Psicosis; Parkinson enfermedad; Alucinación; Delirio; Sistema nervioso patología; Recomendación</SD>
<LO>INIST-20953.354000183361080020</LO>
<ID>08-0199275</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001318 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001318 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0199275
   |texte=   Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations

Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri